People
Candidates pointed out ways they would use the power of the federal government to lower the cost of medications in the United States.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation No 596/2014.
Former Celgene and Wyeth leader with 30 years of global biopharmaceutical experience joins company as it prepares for first Biologics License Application (BLA) submission
Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces the appointments of Dr Alex Jackson as Head of Research and Development and of Archie Hale as Director of Clinical Operations.
Emma Walmsley, chief executive officer of GlaxoSmithKline, is predicting a good year for her company, with the potential of six regulatory approvals in the United States.
The deal will increase the availability of next-generation sequencing-based in vitro diagnostic (IVD) tests on Illumina’s diagnostic sequencing systems.
With a massive $200 million Series A financing round, EQRx launches with the mission of creating novel medicines that are more affordable for patients and more sustainable for healthcare systems.
As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
Turbine, a simulation-first drug discovery company, announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.
Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, announced that Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020.
PRESS RELEASES